Cargando…
Antiviral Compounds from Myxobacteria
Viral infections including human immunodeficiency virus (HIV), cytomegalovirus (CMV), hepatitis B virus (HBV), and hepatitis C virus (HCV) pose an ongoing threat to human health due to the lack of effective therapeutic agents. The re-emergence of old viral diseases such as the recent Ebola outbreaks...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6163824/ https://www.ncbi.nlm.nih.gov/pubmed/30029487 http://dx.doi.org/10.3390/microorganisms6030073 |
_version_ | 1783359454139383808 |
---|---|
author | Mulwa, Lucky S. Stadler, Marc |
author_facet | Mulwa, Lucky S. Stadler, Marc |
author_sort | Mulwa, Lucky S. |
collection | PubMed |
description | Viral infections including human immunodeficiency virus (HIV), cytomegalovirus (CMV), hepatitis B virus (HBV), and hepatitis C virus (HCV) pose an ongoing threat to human health due to the lack of effective therapeutic agents. The re-emergence of old viral diseases such as the recent Ebola outbreaks in West Africa represents a global public health issue. Drug resistance and toxicity to target cells are the major challenges for the current antiviral agents. Therefore, there is a need for identifying agents with novel modes of action and improved efficacy. Viral-based illnesses are further aggravated by co-infections, such as an HIV patient co-infected with HBV or HCV. The drugs used to treat or manage HIV tend to increase the pathogenesis of HBV and HCV. Hence, novel antiviral drug candidates should ideally have broad-spectrum activity and no negative drug-drug interactions. Myxobacteria are in the focus of this review since they produce numerous structurally and functionally unique bioactive compounds, which have only recently been screened for antiviral effects. This research has already led to some interesting findings, including the discovery of several candidate compounds with broad-spectrum antiviral activity. The present review looks at myxobacteria-derived antiviral secondary metabolites. |
format | Online Article Text |
id | pubmed-6163824 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-61638242018-10-10 Antiviral Compounds from Myxobacteria Mulwa, Lucky S. Stadler, Marc Microorganisms Review Viral infections including human immunodeficiency virus (HIV), cytomegalovirus (CMV), hepatitis B virus (HBV), and hepatitis C virus (HCV) pose an ongoing threat to human health due to the lack of effective therapeutic agents. The re-emergence of old viral diseases such as the recent Ebola outbreaks in West Africa represents a global public health issue. Drug resistance and toxicity to target cells are the major challenges for the current antiviral agents. Therefore, there is a need for identifying agents with novel modes of action and improved efficacy. Viral-based illnesses are further aggravated by co-infections, such as an HIV patient co-infected with HBV or HCV. The drugs used to treat or manage HIV tend to increase the pathogenesis of HBV and HCV. Hence, novel antiviral drug candidates should ideally have broad-spectrum activity and no negative drug-drug interactions. Myxobacteria are in the focus of this review since they produce numerous structurally and functionally unique bioactive compounds, which have only recently been screened for antiviral effects. This research has already led to some interesting findings, including the discovery of several candidate compounds with broad-spectrum antiviral activity. The present review looks at myxobacteria-derived antiviral secondary metabolites. MDPI 2018-07-19 /pmc/articles/PMC6163824/ /pubmed/30029487 http://dx.doi.org/10.3390/microorganisms6030073 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Mulwa, Lucky S. Stadler, Marc Antiviral Compounds from Myxobacteria |
title | Antiviral Compounds from Myxobacteria |
title_full | Antiviral Compounds from Myxobacteria |
title_fullStr | Antiviral Compounds from Myxobacteria |
title_full_unstemmed | Antiviral Compounds from Myxobacteria |
title_short | Antiviral Compounds from Myxobacteria |
title_sort | antiviral compounds from myxobacteria |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6163824/ https://www.ncbi.nlm.nih.gov/pubmed/30029487 http://dx.doi.org/10.3390/microorganisms6030073 |
work_keys_str_mv | AT mulwaluckys antiviralcompoundsfrommyxobacteria AT stadlermarc antiviralcompoundsfrommyxobacteria |